A RANDOMISED CONTROLLED TRIAL OF LOW-DOSE KETAMINE IN YOUTH WITH SEVERE DEPRESSION AND ELEVATED SUICIDE RISK

Grant number: 1138736 | Funding period: 2018 - 2023

Active

Abstract

Recent research has shown that a single injection of low-dose ketamine has powerful, though short-lived, antidepressant effects. Effective treatments are urgently needed for young people with severe depression. This will be the first controlled study to test whether repeated doses of ketamine, given over 4 weeks, is effective for young patients.

Related publications (2)

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

Daniel Perkins, Jerome Sarris, Susan Rossell, Yvonne Bonomo, David Forbes, Christopher Davey, Daniel Hoyer, Colleen Loo, Greg Murray, Sean Hood, Violeta Schubert, Nicole Leite Galvao-Coelho, Meaghen O'Donnell, Olivia Carter, Paul Liknaitzky, Martin Williams, Dan Siskind, David Penington, Michael Berk, David Castle

2021-03-21

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphet..

Ketamine and rapidly acting antidepressants: Breaking the speed of sound or light?

Michael Berk, Collen Loo, Christopher G Davey, Brian H Harvey

2018-11-01

There is an urgent need for rapidly acting antidepressants. Current therapies share a delayed onset of action, contrasting with dr..

University of Melbourne Researchers

Chris Davey Psychiatry

Susan Cotton Centre for Youth Mental Health

Paul Amminger Centre for Youth Mental Health

Ben Harrison Psychiatry